**Ordinary General Meeting of Shareholders of Probiodrug AG**  
***All proposed resolutions approved with large majority***

**HALLE (SAALE), Germany, 22 June 2018** - Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announces that its Ordinary General Meeting of shareholders was held on 21 June 2018 in Berlin.

38.26 % of the voting shares were represented at the 2018 Probiodrug AG AGM.

All resolutions proposed by the Company's Management and Supervisory Board were approved at the meeting with a large majority. The Voting results can be found on the company Homepage: <http://www.probiodrug.de/investors/annual-shareholders-meeting-2018/>

**Dr Ulrich Dauer, Chief Executive Officer of Probiodrug AG, said:** "We would like to take the opportunity to thank all our employees, advisors and consultants, members of the supervisory board, partners and shareholders for their commitment, trust and support."

###

**For more information, please contact:**  
**Probiodrug**  
Dr Ulrich Dauer, CEO  
Email: [contact@probiodrug.de](mailto:contact@probiodrug.de)

**Optimum Strategic Communications**  
Mary Clark, Supriya Mathur, Hollie Vile  
Tel: +44 (0) 203 714 1787  
Email: [probiodrug@optimumcomms.com](mailto:probiodrug@optimumcomms.com)

**Solebury Trout**  
Michael Levitan  
Tel: +1 (646) 378-2920  
Email: [MLevitan@troutgroup.com](mailto:MLevitan@troutgroup.com)

**MC Services AG**  
Anne Hennecke, Caroline Bergmann  
Tel: +49 (0) 211 529 252 20  
Email: [probiodrug@mc-services.eu](mailto:probiodrug@mc-services.eu)

**Notes to Editors:**  
**About Probiodrug AG**  
Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a clinical stage biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease (AD). Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting a key neuro-/synaptotoxic component of the pathology, pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy. The enzyme Glutaminyl Cyclase (QC) plays a central role in this process.

Its lead product, PQ912, has successfully completed a Phase 2a (SAPHIR) study. The company's pipeline also includes PBD-C06, an anti-pGlu-Abeta-specific monoclonal antibody, in preclinical development. Probiodrug has medical use and composition of matter patents related to the inhibition of QC and anti-pGlu-Abeta-specific monoclonal antibodies, and has, in the Company's view, a leading position in this field of research.

**About PQ912**  
PQ912, is a first in class, highly specific and potent inhibitor of Glutaminyl Cyclase (QC), the enzyme catalyzing the formation of synaptotoxic pGlu-Abeta. PQ912 has shown therapeutic effects in AD animal models. A Phase-1 study in healthy young and elderly volunteers revealed a dose dependent exposure and showed good safety and tolerability up to the highest dose resulting in >90% target occupancy in the spinal fluid. In June 2017, Probiodrug announced top-line data of the Phase-2a SAPHIR trial of PQ912 and presented the study results at CTAD 2017. Results strongly support (a) the hypothesis of pGlu-Abeta being synaptotoxic and (b) the therapeutic concept pursued by Probiodrug. The study provides important guidance how to move forward with the development of PQ912 as a disease-modifying drug for AD. Altogether, the results make the program highly attractive for further development; the company has initiated the preparation of a Phase 2b core program.

[www.probiodrug.de](http://www.probiodrug.de/)

**About Alzheimer's disease**  
Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as the global population ages. Dementia also has a huge economic impact. Alzheimer's has an estimated, global societal cost of US$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016).

***Forward Looking Statements***  
*Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*